United States· US:63090-340_eccfc06d-c43d-45d6-b172-414f8de9865a
NUPLAZID
A pimavanserin product containing pimavanserin tartrate, registered in United States by Acadia Pharmaceuticals Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- pimavanserin tartrate
- Manufacturer
- Acadia Pharmaceuticals Inc.
- Country
- United States (US)
- ATC code
- N05AX17
- ATC class
- Pimavanserin
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc11630903403030 CAPSULE in 1 BOTTLE, PLASTIC (63090-340-30)
Regulatory notes
Interactions
207 interactions on record for pimavanserin.
Graded by severity as the source publishes them — 48 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pimavanserin · interactions on record
207 records
- 48 severe
- 157 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PapaverinC04AX38severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N05AX17
Pimavanserin, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/afab660c-edf3-40d2-b2f1-9561d864ee6b GET /v1/drugs/afab660c-edf3-40d2-b2f1-9561d864ee6b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "NA83F1SJSR",
"rxcui": "1791686",
"inchikey": "RGSULKHNAKTFIZ-CEAXSRTFSA-N",
"display_name": "PIMAVANSERIN TARTRATE",
"substance_type": "chemical",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "ORAL",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"spl_meta": {
"1e6bea44-57d6-4bac-9328-46e1ee59f83b": {
"match": "brand_token",
"title": "NUPLAZID (PIMAVANSERIN TARTRATE) CAPSULE NUPLAZID (PIMAVANSERIN TARTRATE) TABLET, COATED [ACADIA PHARMACEUTICALS INC.]",
"spl_version": "22",
"published_date": "2026-05-20"
}
},
"productid": "63090-340_eccfc06d-c43d-45d6-b172-414f8de9865a",
"productndc": "63090-340",
"dosage_form": "CAPSULE",
"orange_book": {
"appl_no": "210793",
"products": [
{
"rs": true,
"rld": true,
"te_code": null,
"strength": "EQ 34MG BASE",
"product_no": "001",
"approval_date": "Jun 28, 2018"
}
],
"appl_type": "N"
},
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "PIMAVANSERIN TARTRATE",
"proprietary_name": "NUPLAZID",
"active_ingred_unit": "mg/1",
"application_number": "NDA210793",
"marketing_category": "NDA",
"nonproprietary_name": "pimavanserin tartrate",
"start_marketing_date": "20180628",
"active_numerator_strength": "34"
}See everything about pimavanserin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.